The current standard of care model for newly diagnosed fit multiple myeloma (NDMM)
patients is the sequential treatment of induction, high dose melphalan, autologous stem cell …

Background CD38 has been established as an important therapeutic target for multiple
myeloma (MM), for which two CD38 antibodies are currently approved—daratumumab and …

Background Anti-CD38 monoclonal antibodies have consistently shown increased efficacy
when added to standard of care for patients with multiple myeloma. We aimed to assess the …

Background For patients with newly diagnosed multiple myeloma, reaching minimal residual
disease (MRD) negativity after treatment is associated with improved outcomes; however …

Multiple myeloma (MM) is a hematologic malignancy characterized by clonal proliferation of
plasma cells. MM is a heterogeneous disease, featured by various molecular subtypes with …

The introduction of high-dose therapy in the 1990s as well as the development of drugs such
as thalidomide, lenalidomide, and bortezomib in the 2000s led to an impressive …

Historically, multiple myeloma has been considered an incurable disease, mainly because
of its recurrence after transient control. However, the landscape of multiple myeloma …

Background Limited data are available on the concordance between multiparameter flow
cytometry (MFC) and next-generation sequencing (NGS) for minimal residual disease …

Multiple Myeloma (MM), the second most common hematologic malignancy, has been the
target of many therapeutic advances over the past two decades. The introduction of novel …

We evaluated the efficacy and safety of 24 cycles of Dara in combination with carfilzomib (K),
lenalidomide (R), and dexamethasone (d) without autologous stem cell transplant (ASCT) in …